Pharmacotherapy Specialty Recertification Literature Study: Fall Module 2A-C (L269182)

ACPE Numbers: Various – see listing below
Content Release Date: October 14, 2026
Expiration Dates: October 12, 2027
Activity Type: Application-based
CE Credits: 10 hours (BPS and ACPE)
Activity Fee: $65 (ASHP member); $120 (non-member), free for plan users

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 3 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles.

Module 2A – Cardiology: This module includes topics related to cardiology. Articles include the new Acute Coronary Syndrome (ACS) guidelines, and studies examining aspirin duration following ACS, extended treatment of venous thromboembolism, and baxdrostat use in hypertension.

Module 2B – Infectious Diseases: This module includes topics related to infectious diseases. Articles include adult sinusitis guidelines and a review of sulopenem etzadroxil and probenicid, as well as studies related to glucocorticoid use in pneumonia and treatment of uncomplicated urinary tract infections.

Module 2C – Acute Care: This module includes topics on various therapeutic areas. Articles include a toxicology update, phenobarbital use in alcohol withdrawal, and a review on superficial vein thrombosis.

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

These activities are part of the ASHP professional development program for BCPS recertification approved by the BPS.

Accreditation

Target Audience

Recertification Credit

Board certified pharmacists are eligible to receive up to 10 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

ASHP is approved by BPS as a provider for the recertification of BCPS.

Learning Activity	ACPE Number	Contact Hours (ACPE and BPS)	Assessment Pass Point
Module 2A: Cardiology	0204-0000-26-959-H01-P	5.0	72%
Module 2B: Infectious Diseases	0204-0000-26-960-H01-P	3.0	73%
Module 2C: Acute Care	0204-0000-26-961-H01-P	2.0	70%

Articles and Learning Objectives

Module 2A: Cardiology

ACPE #: 0204-0000-26-959-H01-P

This module includes topics related to cardiology. Articles include the new Acute Coronary Syndrome (ACS) guidelines, and studies examining aspirin duration following ACS, extended treatment of venous thromboembolism, and baxdrostat use in hypertension.

Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2025; 151(13): e771-862.
FOCUS ON: Focus on: Sections 2, 3, 4, 5, 11

Describe the 2025 guideline for the management of patients with acute coronary syndromes (ACS) from the American College of Cardiology, American Heart Association, and other organizations
Develop recommendations for the management of patients with acute coronary syndromes (ACS)

Tarantini G, Honton B, Paradies V, et al; TARGET-FIRST Investigators. Early discontinuation of aspirin after PCI in low-risk acute myocardial infarction. N Engl J Med. 2025;393(21):2083-2094

Describe the TARGET-FIRST study by Tarantini and colleagues of early discontinuation of aspirin therapy after percutaneous coronary intervention (PCI) and successful complete revascularization for acute myocardial infarction
Apply the results from the TARGET-FIRST trial of the timing of discontinuation of aspirin therapy after the use of dual antiplatelet therapy (DAPT) in patients who underwent percutaneous coronary intervention (PCI) and successful revascularization for acute myocardial infarction to patient care, taking into consideration patient characteristics (e.g., risk for ischemic events, risk for bleeding)
Interpret the results of the TARGET-FIRST trial of the timing of discontinuation of aspirin therapy after the use of dual antiplatelet therapy (DAPT) in patients who underwent percutaneous coronary intervention (PCI) and successful revascularization for acute myocardial

Guimarães PO, Franken M, Tavares CAM, et al; NEO-MINDSET Trial Investigators. Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. N Engl J Med. 2025 Nov 27;393(21):2095-2106.

Describe the Percutaneous Coronary Intervention Followed by Monotherapy Instead of Dual Antiplatelet Therapy in the Setting of Acute Coronary Syndromes (NEO-MINDSET) trial by Guimarães and colleagues
Interpret the results of the NEO-MINDSET trial of early withdrawal of aspirin after percutaneous coronary intervention (PCI) in patients with acute coronary syndromes receiving dual antiplatelet therapy (DAPT).

Lemesle G, Didier R, Steg PG, et al. Aspirin in patients with chronic coronary syndrome receiving oral anticoagulation. N Engl J Med 2025; 393: 1578-1588. (AQUATIC Trial)

Describe the Assessment of Quitting versus Using Aspirin Therapy in Patients with Stabilized Coronary Artery Disease after Stenting Who Require Long-Term Oral Anticoagulation (AQUATIC) trial by Lemesle and colleagues
Develop recommendations for the use of aspirin therapy in patients with chronic coronary syndrome and implanted coronary stents who are at high atherothrombotic risk and receiving long-term oral anticoagulation

Piazza G, Bikdeli B, Pandey AK, et al for the HI-PRO Trial Investigators. Apixaban for extended treatment of provoked venous thromboembolism. N Engl J Med. 2025;393(12):1166-1176

Describe the Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients with Provoked Venous Thromboembolism (HI-PRO) study by Piazza and colleagues
Develop recommendations for the duration of anticoagulation in patients with provoked venous thromboembolism (VTE) and enduring risk factors for recurrence

Flack JM, Azizi M, Brown JM, et al. for the BaxHTN Investigators. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025;393(14):1363. Epub 2025 Aug 30.

Describe the BaxHTN study by Flack and colleagues of the efficacy and safety of baxdrostat for treating uncontrolled or treatment-resistant hypertension
Develop recommendations for the use of baxdrostat as add-on therapy for patients with uncontrolled or treatment-resistant hypertension

Module 2B: Infectious Diseases
ACPE #: 0204-0000-26-960-H01-P

This module includes topics related to infectious diseases. Articles include adult sinusitis guidelines and a review of sulopenem etzadroxil and probenicid, as well as studies related to glucocorticoid use in pneumonia and treatment of uncomplicated urinary tract infections.

Lucinde RK, Gathuri H, Mwaniki P, et alPragmatic Trial of Glucocorticoids for Community Acquired Pneumonia. N Engl J Med 2025;393:2187-97. DOI: 10.1056/NEJMoa2507100

Describe the Steroids in Pneumonia (SONIA) pragmatic trial by Lucinde and colleagues of the use of adjunctive glucocorticoids for community-acquired pneumonia (CAP)
Develop recommendations for the use of adjunctive glucocorticoids in adults with community-acquired pneumonia (CAP)

Payne SC, McKenna M, Buckley J, et al. Clinical Practice Guideline: Adult Sinusitis Update. Otolaryngol Head Neck Surg. 2025; 173: S1-S56. https://doi.org/10.1002/ohn.1344
Focus on: Statements 1A (pS6-S11); Stmt 2 (S12-14) Stmt 3 (S14-16); Stmt 4 (S16-18); Stmt 5 (S18-21); Stmt 6 (S21-23); Stmt 11 (S35-37); Stmt 12 (S37-38); Stmt 14 (S41-42)

Describe the differential diagnosis and pharmacologic management of rhinosinusitis based on the updated clinical practice guideline on adult sinusitis from the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO–HNSF)
Develop recommendations for the differential diagnosis and pharmacologic management of adults with rhinosinusitis

Ocheretyaner E, Melgar K, Kalabalik-Hoganson J. Sulopenem etzadroxil and probenecid: A drug review of a novel oral penem active against ESBL-producing bacteria. Am J Health-Syst Pharm. 2026; 83: e6–e11, https://doi.org/10.1093/ajhp/zxaf220

Describe the mechanism of action, pharmacodynamic and pharmacokinetic properties, and available clinical evidence supporting the use of sulopenem etzadroxil and probenecid for the treatment of urinary tract infections and intra-abdominal infection.
Develop recommendations for the use of sulopenem etzadroxil and probenecid in patients with urinary tract infection

Mitzner TM, Eid KM, Hughson DM, Jameson AP, Dumkow LE. Cefdinir versus cephalexin for the treatment of uncomplicated urinary tract infections. Open Forum Infect Dis. 2025;12(10):ofaf501. https://doi.org/10.1093/ofid/ofaf501

Describe the study by Mitzner and colleagues comparing oral cefdinir with cephalexin for the treatment of uncomplicated urinary tract infection (uUTI) or acute cystitis
Develop recommendations for the treatment of adult female outpatients with symptomatic uncomplicated UTI (uUTI) or acute cystitis

Module 2C: Acute Care
ACPE #: 0204-0000-26-961-H01-P

This module includes topics on various therapeutic areas. Articles include a toxicology update, phenobarbital use in alcohol withdrawal, and a review on superficial vein thrombosis.

Feldman R, Lund J, Rivera Pescatore J, Stanton Mathew. Toxicology updates in emergency Medicine. Am J Health-Syst Pharm 2025:82:1362 - 1376.

Describe key toxicology topics currently relevant to emergency medicine pharmacists, including recent toxicology treatment guidelines, available evidence for the use of established antidotes, and toxicities associated with the evolving landscape of illicit substances.
Develop recommendations for the management of toxicological emergencies at the bedside and at the institutional level through protocol development and formulary management

Wolpaw BJ, Oren H, Quinnan-Hostein L, et al. Hospital-wide implementation, clinical outcomes, and safety of phenobarbital for alcohol withdrawal. JAMA Network Open. 2025; 8(8):e2528694

Describe the study by Wolpaw and colleagues of implementation of a phenobarbital electronic health record order set for alcohol withdrawal syndrome (AWS) in all care locations in a community hospital
Develop recommendations for the use of a phenobarbital electronic health record order set for patients with alcohol withdrawal syndrome.

Piazza G, Krishnathasan D, Hamade N, et al. Superficial Vein Thrombosis: A Review. JAMA. 2025 Sep 15. doi: 10.1001/jama.2025.15222. Epub ahead of print. PMID: 40952730

Describe the pathophysiology, etiology, epidemiology, clinical presentation, diagnosis, treatment, and prognosis of superficial vein thrombosis
Develop recommendations for the diagnosis and treatment of patients with superficial vein thrombosis

Faculty

Full Faculty Bios

Christopher Betz, PharmD, BCPS, FASHP, FKSHP*
Clinical Pharmacist Practitioner – Cardiology/Pharmacogenomics
Robley Rex VA Medical Center
Adjunct Professor
Louisville, Kentucky

Tina Beck, PharmD, MSCR, BCPS
Associate Professor
University of the Incarnate Word
San Antonio, Texas

Snehal H. Bhatt, PharmD, AACC, BCPS-AQ Cardiology, FASHP*
Professor of Pharmacy Practice Massachusetts College of Pharmacy and Health Sciences
Framingham, Massachusetts

Dannielle Brown, PharmD, BCPS
Pharmacy Clinical Specialist, Internal Medicine
The Johns Hopkins Hospital
Baltimore, Maryland

Heather Draper, PharmD, BCPS, BCEMP
Clinical Pharmacist
Trinity Health
Grand Rapids, Michigan

Lauren Floris, PharmD, BCPS, BCCCP
Clinical Pharmacist
Atrium Health
Macon, Georgia

Shannon Haar, PharmD, BCPS
Clinical Assistant Professor
Philadelphia College of Pharmacy
Philadelphia, Pennsylvania

Lauren Igneri, PharmD, BCPS, BCCCP, FCCM
Clinical Pharmacy Specialist, Critical Care
Cooper University Health Care
Camden, New Jersey

Zachary Klick, PharmD, BCACP, BCCP, BCPS, CPP
Cardiology Pharmacist
PGY2 Cardiology Residency Program Director
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina

Samantha Luciana, PharmD, BCPS, BCEMP
Clinical Pharmacy Specialist, Emergency Medicine
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania

Katherine Lusardi, PharmD, BCIDP*
Clinical Pharmacy Specialist, Infectious Diseases
Baptist Health
Little Rock, Arkansas

Brooklyn Olumba, PharmD, BCPS*
Clinical Pharmacy Specialist, Ambulatory Care
Memorial Hermann Southwest Hospital
Houston, Texas

Lalita Prasad-Reddy, PharmD, MS, BCACP, BCPS, CDE
Assistant Dean for Preclerkship Education, Chicago Medical School
Clinical Pharmacy Specialist, Rush University Medical Center
Chicago, Illinois

*Content Matter Experts

Reviewers

Field Testers

Mohamed Amar, PharmD, BCPS, BCCP, MS
Kayla Einhaus, PharmD, BCPS
Noah Fang, PharmD, BCPS
Erin Farrell, PharmD, BCPS
Elizabeth Getselevich, PharmD, BCPS
Denise Kelley, PharmD, BCPS, FASHP
Yvonne Labram, PharmD, BCPS
Emma Larson, PharmD, BCPS
Susan Lowrie, PharmD, BCGP, BCPS
Erin Mangum, PharmD, BCPS
Shane McMahon, PharmD, BCPS, BCCCP
Drew Nevala, PharmD, BCPS, CDCES
David Ngo, PharmD, BCPS, MBA
Kristin Quarterman, PharmD
Alyssa Robertson, PharmD, MEd, BCPS, BCCCP, BCEMP
Caroline Schmidt, PharmD, BCPS, BCACP
Tova Shulman, PharmD, BCPS
Hillary Szuch, PharmD, BCPS
Sherwyn Tenia, PharmD, MBA, BCPS, PMP
Ashley Thrasher, PharmD, BCPS
Caleb VonStein, PharmD, BCPS
Mike Yaros, PharmD, BCPS, BCCP
Jeffrey Yochum, PharmD, BCPS

Relevant Financial Relationship Disclosures

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

The following persons in control of this activity’s content have relevant financial relationships:

Samantha Luciana: Consultant, Lucid Group
Lauren Igneri: Consultant, Serb Pharmaceuticals
All other planners, presenters, reviewers, ASHP staff, and others with an opportunity to control content report no financial relationships relevant to this activity.

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Methods and CE Requirements

Development

Board Recert

Member

Non-Member

Activity Overview

Error